Overview

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Status:
RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
AbbVie
Syndax Pharmaceuticals
Treatments:
revumenib
venetoclax